Effectiveness and safety of vedolizumab induction with or without budesonide in patients with moderately to severely active Crohn’s disease in Europe: a retrospective observational study

Abstract Background Vedolizumab (VDZ), a gut-selective anti-lymphocyte trafficking integrin antibody, is effective in treating patients with moderately to severely active Crohn’s disease (CD). In this study, we examined the real-world effectiveness and safety of induction therapy using VDZ alone or...

Full description

Bibliographic Details
Published in:	BMC Gastroenterology
Main Authors:	Roni Weisshof, Stephan R. Vavricka, Lieven Pouillon, Fiona Braegger, Montserrat Roset, Nawal Bent-Ennakhil, Marc Ferrante
Format:	Article
Language:	English
Published:	BMC 2023-11-01
Subjects:	Budesonide Crohn’s disease Moderately to severely active crohn’s disease Vedolizumab
Online Access:	https://doi.org/10.1186/s12876-023-03032-7

Similar Items

Efficacy and Safety of Natalizumab and Vedolizumab in the Treatment of Crohn’s Disease: A Systematic Review and Meta-Analysis
by: Ni Putu Sri Indrani Remitha, et al.
Published: (2025-09-01)

The Efficacy of Combination Therapy with Ustekinumab and Budesonide for Crohn’s Disease: A Randomized Controlled Trial
by: Rintaro Moroi, et al.
Published: (2023-11-01)

Comparative effectiveness of ustekinumab vs. vedolizumab for anti-TNF-naïve or anti-TNF-exposed Crohn's disease: a multicenter cohort studyResearch in context
by: Hongsheng Yang, et al.
Published: (2023-12-01)

Vedolizumab combined with surgical resection successfully treated perforating Crohn’s disease with peritoneal space to rectal and vaginal fistulas: a case report
by: Meng-Wu Chung, et al.
Published: (2021-07-01)

Comparison of surgery rates in biologic-naïve patients with Crohn’s disease treated with vedolizumab or ustekinumab: findings from SOJOURN
by: Michelle Vu, et al.
Published: (2023-03-01)

Comparison of the Efficacy of Vedolizumab and Ustekinumab in Biologic-naïve Patients with Moderately to Severely Active Crohn's Disease
by: LIU Liu, XU Wenhang, LYU Bin, FAN Yihong
Published: (2025-03-01)

Vedolizumab treatment in a patient with X-linked agammaglobulinemia, is it safe and efficient?
by: Şükrü Çekiç, et al.
Published: (2019-12-01)

Comparison of the Safety and Efficacy of Ustekinumab and Vedolizumab in Patients with Crohn’s Disease: A Systematic Review and Meta-Analysis of Propensity Score Matched Cohort Studies
by: Andrea Pasta, et al.
Published: (2024-11-01)

Magnetic Resonance Enterography Assessment of Transmural Healing with Vedolizumab in Moderate to Severe Crohn’s Disease: Feasibility in the VERSIFY Phase 3 Clinical Trial
by: Rimola J, et al.
Published: (2024-01-01)

Case report: Vedolizumab in Oral Crohn’s disease: the downsides of a gut-specific therapy for a multi-site disease
by: Molly Harte, et al.
Published: (2024-12-01)

Short term effectiveness of ustekinumab versus vedolizumab in Crohn’s disease after failure of anti-TNF agents: An observational comparative study design with a Bayesian analysis
by: Ahmad Alamer, et al.
Published: (2024-09-01)

Cost per responder for vedolizumab and ustekinumab in Crohn’s disease patients after failure of TNF-α inhibitors in Italy
by: Roberto Ravasio, et al.
Published: (2023-01-01)

Efficacy of ustekinumab, vedolizumab, or a second anti-TNF agent after the failure of a first anti-TNF agent in patients with Crohn’s disease: a multicentre retrospective study
by: Rayer Cassandra, et al.
Published: (2022-12-01)

Remission Is Maintained after Switch from Dose-Optimised Intravenous Treatment to Subcutaneous Treatment with Vedolizumab in Inflammatory Bowel Disease
by: Špela Pintar, et al.
Published: (2024-02-01)

Colon and Rectal Surgery for Inflammatory Bowel Disease Patients on Vedolizumab: Preliminary Surgical Outcomes
by: Sarah B. Stringfield, et al.
Published: (2018-01-01)

A product review of vedolizumab in inflammatory bowel disease
by: Robert Battat, et al.
Published: (2019-10-01)

The Efficacy and Safety of Biologic Drugs in the Treatment of Moderate–Severe Crohn’s Disease: A Systematic Review
by: Ana Avedillo-Salas, et al.
Published: (2023-11-01)

Real-world clinical effectiveness and safety of vedolizumab and anti-tumor necrosis factor alpha treatment in ulcerative colitis and Crohn’s disease patients: a German retrospective chart review
by: Ulf Helwig, et al.
Published: (2020-07-01)

The role of vitamin D deficiency and modifiable risk factors in patients with Crohn’s disease
by: Xiaoyue Feng, et al.
Published: (2025-07-01)

Vedolizumab does not increase risk of clostridium difficile infection in patients with inflammatory bowel disease using vedolizumab: A retrospective cohort study
by: Abdulaziz Saad Alshahrani, et al.
Published: (2023-09-01)

Safety and efficacy of vedolizumab in pediatric inflammatory bowel disease with emphasis on the very-early-onset group
by: Sylwia Fabiszewska, et al.
Published: (2023-06-01)

Role of Gut Microbiota and Metabolomics in Predicting Response to Vedolizumab in Inflammatory Bowel Disease: A Systematic Review
by: Vaidota Malinauskiene, et al.
Published: (2025-04-01)

Short-term efficacy of vedolizumab in patients with inflammatory bowel disease in real-life settings in Bosnia and Herzegovina
by: Nermin Salkić, et al.
Published: (2024-04-01)

IgA Nephropathy in a Patient Treated with Adalimumab
by: Tonja Mertelj, et al.
Published: (2021-07-01)

Emerging Therapies: What Are Promising in the Near Future?
by: Geom Seog Seo, et al.
Published: (2018-02-01)

Comparative effectiveness of second-line biological therapies for ulcerative colitis and Crohn’s disease in patients with prior failure of anti-tumour necrosis factor treatment
by: Hye Kyung Hyun, et al.
Published: (2022-03-01)

High-Throughput Whole-Exome Sequencing and Large-Scale Computational Analysis to Identify the Genetic Biomarkers to Predict the Vedolizumab Response Status in Inflammatory Bowel Disease Patients from Saudi Arabia
by: Hanin Aljohani, et al.
Published: (2025-02-01)

Terminal ileitis: Questions of differential diagnosis and prospects for treatment. A review
by: Alexey M. Osadchuk, et al.
Published: (2025-01-01)

Gastrointestinal endoscopy for intestinal dysplasia and neoplasia detection and management in Crohn’s disease: when and how?
by: Tommaso Pessarelli, et al.
Published: (2025-07-01)

Segundo Consenso Mexicano de terapia biológica y moléculas pequeñas en enfermedad inflamatoria intestinal
by: J.K. Yamamoto-Furusho, et al.
Published: (2021-01-01)

BIOLOGICAL THERAPY IN ADULT PATIENTS WITH ULCERATIVE COLITIS AND CROHN’S DISEASE: BUDGET IMPACT ANALYSIS
by: E. A. Pyadushkina
Published: (2017-05-01)

Pharmacogenetics of Biological Agents Used in Inflammatory Bowel Disease: A Systematic Review
by: Rita Lauro, et al.
Published: (2021-11-01)

Interleukin‐12/23 and Interleukin‐23 Inhibitors for the Treatment of Cutaneous Crohn's Disease: A Case Series From a Multi‐Institutional Registry
by: G. E. McKay, et al.
Published: (2025-06-01)

Progress and Clinical Applications of Crohn’s Disease Exclusion Diet in Crohn’s Disease
by: Duo Xu, et al.
Published: (2024-05-01)

Location-specific signatures of Crohn’s disease at a multi-omics scale
by: Carlos G. Gonzalez, et al.
Published: (2022-08-01)

Association of Periodontal Disease with Activity of Crohn’s Disease
by: Miloš Živić, et al.
Published: (2023-12-01)

Efficacy and Safety of Upadacitinib and Vedolizumab Combination for Refractory Orofacial Granulomatosis Associated with Panenteric Crohn’s Disease: A Case Report
by: Michele Campigotto, et al.
Published: (2025-03-01)

Vedolizumab in the treatment of inflammatory bowel diseases: whom and how?
by: A. O. Golovenko, et al.
Published: (2018-10-01)

ModuLifeTM- a novel dietary approach in management of a patient with moderate Crohn’s disease
by: Alisa Fejzić, et al.
Published: (2023-01-01)

The endoscopic prediction model of simple endoscopic score for Crohn’s disease (SES-CD) as an effective predictor of intestinal obstruction in Crohn’s disease: A multicenter long-term follow-up study
by: Weimin Xu, et al.
Published: (2022-09-01)